These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 10210764)

  • 41. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
    Ozono S; Okajima E; Hirao YK; Natsume O; Kaneko Y; Ohara S; Tabata S; Watanabe S; Aoyama H; Sasaki K; Matsuki H; Takashima K; Maruyama Y; Yoshikawa M; Yamada K; Momose H; Hiramatsu T; Hayashi Y; Babaya K; Shiomi T
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):349-56. PubMed ID: 9051139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
    Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
    J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer].
    Kurita A; Takashima S; Nakata M; Kubo Y; Saiki T; Ohsumi S; Yokoyama N; Tanada M; Takiyama W; Saeki H
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):49-54. PubMed ID: 9020945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1998 Oct; 71(1):113-5. PubMed ID: 9784330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005 Mar; 22(2):103-14. PubMed ID: 15804995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy.
    Spector JI; Lester EP; Chevlen EM; Sciortino D; Harvey JH; Whaley W; Madajewicz S; Isaacs R; Homesley HD; Yee S; Beck TM; Tchekmedyian NS; Crawford KH; Ames M; Creed MR
    Oncologist; 1998; 3(6):432-438. PubMed ID: 10388135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
    Marschner N
    Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral ondansetron for preventing nausea and vomiting.
    Cooke CE; Mehra IV
    Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
    Gralla RJ; Navari RM; Hesketh PJ; Popovic W; Strupp J; Noy J; Einhorn L; Ettinger D; Bushnell W; Friedman C
    J Clin Oncol; 1998 Apr; 16(4):1568-73. PubMed ID: 9552067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment.
    Chiara S; Campora E; Simoni C; Confalonieri M; Psilogenis M; Rosso R
    Anticancer Res; 1995; 15(4):1597-9. PubMed ID: 7654054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
    Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
    Pectasides D; Dafni U; Aravantinos G; Timotheadou E; Skarlos DV; Pavlidis N; Gaglia A; Kalofonos HP; Fountzilas G
    Anticancer Res; 2007; 27(6C):4411-7. PubMed ID: 18214053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.